Background The treatment of migraine is impeded by several difficulties, among which
insufficient headache relief, side effects, and risk for developing medication overuse …

Global Burden of Disease 2010 study considers migraine as one of the most important
noncommunicable diseases in the world, classifying it third in terms of global prevalence …

Nearly 30 years have passed since the first selective 5-HT1 receptor agonist sumatriptan
became a choice of treatment for migraineurs. Recently, a new class of antimigraine drugs …

Migraine is a highly disabling neurovascular disorder characterized by a severe headache
(associated with nausea, photophobia and/or phonophobia), and trigeminovascular system …

For every person living with disabling primary headaches, recent translational success has
heralded a welcome advance in therapeutic options. After years of research and some …

Objective To review and highlight current literature on emerging acute migraine treatments,
focusing on CGRP receptor antagonists, gepants, and 5‐HT1F receptor agonists (ditans) …

The serotonin receptor agonist triptan drugs (5-HT1B/1D receptor agonists) have been in
use for over 20 years in the abortive management of migraine. Although clearly effective …

Introduction: Migraine is among the most disabling disorders worldwide, with a significant
therapeutic need. Triptans are drugs of choice in the acute attack treatment, but they are …

Migraine is a common, chronic, disorder that is typically characterized by recurrent disabling
attacks of headache and accompanying symptoms, including aura. The aetiology is …

Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex
pathophysiology of migraine has allowed us to make great strides in the development of …